In experimental models in vitro and in vivo, the anti-tumour effect of IFN-α has been demonstrated [11, 17–21] and in the past years, a number of clinical studies have been conducted regarding adjuvant IFN-α therapy. The gene discussed is IFNA1; the disease is neoplasm.